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ABSTRACT: Polo-like kinase 1 (PLK1) is a key regulator of mitosis and a
recognized drug target for cancer therapy. Inhibiting the polo-box domain of
PLK1 oﬀers potential advantages of increased selectivity and subsequently
reduced toxicity compared with targeting the kinase domain. However, many if
not all existing polo-box domain inhibitors have been shown to be unsuitable for
further development. In this paper, we describe a novel compound series, which
inhibits the protein−protein interactions of PLK1 via the polo-box domain. We
combine high throughput screening with molecular modeling and computer-
aided design, synthetic chemistry, and cell biology to address some of the
common problems with protein−protein interaction inhibitors, such as solubility and potency. We use molecular modeling to
improve the solubility of a hit series with initially poor physicochemical properties, enabling biophysical and biochemical
characterization. We isolate and characterize enantiomers to improve potency and demonstrate on-target activity in both cell-
free and cell-based assays, entirely consistent with the proposed binding model. The resulting compound series represents a
promising starting point for further progression along the drug discovery pipeline and a new tool compound to study kinase-
independent PLK functions.
■ INTRODUCTION
Polo-like kinase (PLK1) is a key regulator of cell cycle
progression and is a member of a family of closely related
multifunctional kinases comprising PLK1, PLK2, PLK3, and
PLK4. During mitosis, PLK1 has many crucial functions, from
timely mitotic entry to successful cytokinesis and is critical for
bipolar spindle formation and for correct chromosome
segregation. In clinical terms, PLK1 is dysregulated in a wide
range of human tumors, and its level of expression correlates
with a poor prognosis.1 In addition, numerous cell-line studies
demonstrate that PLK1 overexpression induces a transformed
phenotype in noncancer cell lines, and inhibition of PLK1 can
selectively kill tumor cells.2−6 Drug discovery approaches to
targeting protein kinases have traditionally focussed around the
kinase active site, and such inhibitors of PLK1 show some
promise in the clinic.7,8 However, accompanying toxicity and
the potential for the emergence of resistance are likely to limit
the use of such agents. The development of protein−protein
interaction (PPI) inhibitors provides an alternative and
potentially more selective approach and one, which lends
itself well to targeting PLK1 due to the modular nature of the
enzyme. PLK1 is composed of two main structural elements: a
kinase domain, which phosphorylates a great many proteins
during mitosis, and a polo-box domain (PBD), comprising two
polo-box units, which provides spatio-temporal regulation
through interaction with its substrates.9,10 These two domains
are joined by a linker of approximately 50 residues. The kinase
domain has been crystallized in the presence and absence of
bound inhibitors and shows similarity to many other kinases.11
The PBD has been crystallized in the presence and absence of
bound phosphopeptides, and, in contrast, it has a unique
structure, shared only with other members of the PLK family.12
The PBD oﬀers both the phosphopeptide binding groove and
the more recently described tyrosine pocket10,13−15 as possible
sites for small-molecule inhibition and potentially a means to
overcome some of the problems of kinase inhibitors. In the last
few years, studies on a number of small-molecule inhibitors of
the PBD of PLK1 have been published.16−21 However, recent
work has raised questions over the mechanism of action for
some of these inhibitors, casting doubt over the suitability for
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further development.22 Here, we describe a novel drug-like
series for the inhibition of the PLK1 PBD. We characterize key
members of the series using a panel of cell-free, biophysical,
and cell-based assays to show on-target activity, alongside the
use of molecular modeling to inform synthetic chemistry and
improve physicochemical properties.
■ RESULTS AND DISCUSSION
Fluorescence Polarization Screen Identiﬁes Inhibitors
of the PLK1 Polo-box Domain. A ﬂuorescence polarization
(FP) assay was developed to identify compounds that inhibit
the binding of a consensus phosphopeptide to the PBD
domain of PLK1. The assay was then used to screen a diverse
library of approximately 86 000 compounds as described
previously.23 Some of the primary hits were not reproducible
or were identiﬁed as pan assay interference compounds
(PAINS)24 (Table S1). In some cases, highly ﬂuorescent
compounds (Table S1) also generated false positives. These
compounds were excluded from further development. After
removing these spurious results, the screen yielded a hit rate of
0.06% leaving 53 remaining compounds as robust primary hits.
The primary hits contained a number of promising chemical
scaﬀolds including the recently reported Poloppins.23 In this
paper, we focus on the series of compounds derived from
compound 1 (Table 1).
Following conﬁrmation of activity by repeat screening in the
FP assay, a number of commercially available analogues were
purchased for all primary hits, to generate early structure−
activity relationship (SAR) data. We used the clusters
generated in the library design stage to randomly select
analogues of each hit molecule. These analogues were then
tested by FP (Table 1 and Figure S1). The LHSpT peptide, a
minimal phosphopeptide recognizing the PLK1 PBD,25 was
included as a positive control. All of the compounds in Table 1,
with the exception of compound 5, showed dose-dependent
inhibition of phosphopeptide binding in the FP assay (Figure
S1). Further, additional compound 1 analogues were
purchased and tested in the FP assay; however, at a
concentration of 50 μM, none showed activity above 10%
inhibition in the assay and the inherent poor aqueous solubility
of these compounds prevented testing at higher concentrations
(Table S2). Compound 1 remained the most potent of the
compounds tested. Compounds 2 and 5 indicate the
importance of the terminal phenyl ring, while compounds 3
and 4 highlight the methyl substituent and the sulfur atom in
the benzothiazinone, respectively (Table 1).
Molecular Modeling Informs Synthetic Chemistry To
Improve Solubility. Despite the promising results from FP
screening, we were unable to further characterize the
compounds in biophysical or cell-based assays due to the
observed poor solubility. To remedy this problem, we
attempted to improve the physicochemical properties of
compound 1 to generate compounds that retained activity
while showing increased aqueous solubility. To aid in this
process, we generated binding modes for compound 1 using
molecular docking with Glide. The predicted pose can be seen
in Figure 1.
Compound 1 was docked to two PLK1 PBD structures
(PBDID 3BZI and PDBID 3P37). Interestingly, the compound
is not predicted to bind to the His 538/Lys 540 pincer, which
binds the phosphate group of the phosphopeptide binding
partners.9,26 This is in line with the diﬃculty in disrupting the
strongly bound network of water molecules in this region.10
The predicted binding modes for the two structures show an
excellent overlap, and in both cases, the molecule is predicted
to lie in the phosphopeptide binding groove by stacking on the
residue Trp 414 and extends into a cryptic hydrophobic pocket
lined by Tyr 417, Tyr 421, and Tyr 485. This pocket has
previously been implicated in the binding of artiﬁcial peptide
analogues14 and more recently a subset of natural PLK1
substrates.15 The high Glide XP Scores of −11.7 and −12.1
kcal/mol alongside the MM-GBSA scores of −95.3 and −92.9
kcal/mol were encouraging, and the predicted binding mode
Table 1. FP Results for the Primary Hit Compound 1 and a Set of Its Commercially Available Analoguesa
aAll values represent the mean of three independent experiments ± standard deviation. ND = Not detectable.
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was in line with the SAR derived from the compounds in Table
1, increasing its credibility. In particular, the terminal phenyl
ring ﬁlls the cryptic hydrophobic pocket, the methyl group is
positioned in a small cavity between Leu 119, Val 415, and Tyr
485, and the sulfur atom lies on the hydrophobic surface
formed from the sidechain of Trp 414. Using this model, we
designed and synthesized a series of close analogues of
compound 1 that were predicted to show improved solubility
without having a deleterious eﬀect on the activity. Notably,
changes around the terminal phenyl ring (one edge of which is
solvent-exposed in the putative binding pose) were predicted
to be tolerated. The docking mode suggests that changes to the
ortho, meta, and para positions should all be allowed (see
Figure 1). For ease of synthesis, we focused on changes to this
end of the molecule by amide coupling a number of
commercially available amines to a commercially available
acid. Compounds were selected with high similarity to
compound 1 but with an increased polar atom count. No
changes were made to the sulfone group, alkyl chain, or amide
groups, which link the two ends of the molecule together.
These orient the molecule, and the sulfone is predicted to
make a hydrogen bond with the protein backbone. The
solubility of these analogues is shown in Table 2, where the
turbidity of compounds in aqueous solution is used to indicate
solubility.
Compounds 6 and 9 showed a substantial improvement in
solubility through increased polarity around the terminal
phenyl ring, Crucially, this increase in solubility enabled further
characterization of compound 9 (Figure 2A).
Compound 9 was more active in the FP assay with an IC50
of 36 μM. The improved aqueous solubility for compound 9
also allowed us to determine a Kd of 20 μM using isothermal
titration calorimetry (ITC) (Figure 2B), which is consistent
with the results of the FP assay. As a part of an ongoing
campaign to test the predicted binding mode in Figure 1 and
improve the binding aﬃnity, we designed and tested a number
of further analogues, and among them, compounds (−)−9 and
(+)−9, the pair of enantiomers comprising compound 9, are a
racemic mix (Table 3).
In the FP assay, (−)−9 showed an increase in potency over
the parental compound (24.4 μM), while (+)−9 was
considerably less potent, showing only mild activity (Figure
2C). The predicted binding mode can accommodate both
enantiomers, consistent with some activity for both com-
pounds in the assay, but in one case, the methyl group is
solvent-exposed and in the other, it contacts the protein. This
data is thus commensurate with the predicted binding mode.
Additional analogues added further conﬁdence to the predicted
binding mode (Table 3). For example, the para position of the
phenyl ring can accommodate a number of substitutions
Figure 1. Binding mode of compound 1 to the polo-box domain
(PBD) of PLK1 (PDBID 3BZI) predicted by Glide docking. The
protein is displayed as atom colored space ﬁlling with gray carbons
and the ligand is displayed as atom colored balls and sticks with green
carbons. Only polar hydrogen atoms are displayed, and a selection of
residues are labeled.
Table 2. Solubility of a Set of Compound 1 Analogues Designed to Increase Aqueous Solubilitya
aTurbidity was experimentally determined by measuring absorbance at 625 nm at 250 μM, and values are relative to dimethyl sulfoxide (DMSO).
All turbidity values are the mean of three independent experiments ± standard deviation.
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(compounds 12 and 13), consistent with its lack of protein
contacts in the predicted binding mode. The importance of the
3-thiomorpholinone heterocycle is underlined by a lack of
measurable aﬃnity for compound 16 and this is also in line
with the predicted binding mode, where the amide hydrogen
and carbonyl oxygen in the ring make hydrogen bonds with the
backbone of residue Trp 414. When compound 15 is docked,
the binding mode is maintained, but the bond between the
sulfone group and the thiomorpholinone ring is rotated such
that it still stacks on Trp 414 but no longer makes hydrogen-
bonding contacts with the backbone. This is in line with its
slightly reduced activity (111.5 vs 73.1 μM). Compound 16
loses the stacking as well as the hydrogen-bonding contacts
and is inactive. Conversely, converting the 3-thiomorpholinone
ring to a 3-morpholinone ring (compound 10) retains activity,
consistent with its lack of protein contacts. Although
compound 11 appeared to have improved potency, neither
of the isolated enantiomers, (−)−11 and (+)−11, matched
this improvement. The reason for this observation was not
clear, so this compound was not taken further.
Improved Soluble Analogue Shows on-Target Activ-
ity in Cell-Based Assays. With excellent solubility and in
vitro evidence for target engagement from the FP and ITC
assays (Figure 2), compound 9 was tested for cell-based
activity alongside the isolated enantiomer pair, (−)−9 and
(+)−9. The compounds were tested in a high-content mitotic
index assay designed to identify molecules, which are able to
cause a mitotic arrest (Figure 3A).
Small-molecule inhibition of PLK1 by either kinase
inhibitors28−31 or inhibitors of the polo-box domain23 has
been shown to inhibit timely progression through mitosis,
giving rise to an increased mitotic index. Compound 9 and
(−)−9 both showed a robust increase in mitotic arrest (4-
fold), while (+)−9 gave a much milder eﬀect, conﬁrming that
(−)−9 is the active enantiomer as predicted by the FP assay
results (Figure 2C). In addition, examination of the images
from high-content analysis revealed cells arrested in prom-
etaphase with misaligned chromosomes, a phenotype charac-
teristic of inhibition of PLK1 via the PBD (Figure S2). Closer
examination and quantitation of the mitotic phenotype by
confocal microscopy conﬁrmed that the predominant
phenotype was arrested in prometaphase with a bipolar
spindle and noncongressed chromosomes (Figure 3B,C).
This phenotype has been consistently reported as a direct
result of inhibition of the PBD, and it is distinct from the
monopolar phenotype seen when PLK1 kinase activity is
directly inhibited either by small molecules or by depletion of
the protein using RNA interference.26,32 Thus, these
observations provide strong support that compound (−)−9
is an inhibitor of the PLK1 PBD both in a cell-free setting and
within the cellular milieu.
We sought further evidence that the action of compound
(−)−9 was through inhibition of the PBD of PLK1 by
examining localization of the PLK1 protein in compound-
treated cells. Using a previously described HeLa cell line with a
doxycycline-inducible overexpression of GFP-tagged PLK1,15
we looked at localization of the ﬂuorescently tagged protein in
mitosis. Mutations of the PBD at residues His 538 and Lys 540
within the phosphopeptide binding groove or at residues Tyr
421, Leu 478, and Tyr 481 within the tyrosine pocket have
been shown to disrupt the interaction of PLK1 with critical
mitotic substrates and result in loss of GFP-PLK1 from the
kinetochores.15 This phenotype was recapitulated upon
treatment of cells with compound (−)−9, showing a clear
decrease in kinetochore localization of GFP-PLK1 (Figure 4).
While this provides strong evidence that this compound can
inhibit the PBD of PLK1 in cells, we cannot exclude the
possibility that these compounds may also inhibit the PBD of
other PLK family members. Indeed, a sequence alignment of
the PBD of the PLK family suggests that achieving selectivity
for PLK1 will be challenging but possible. The overall
sequence identity with the PLK1 PBD is 38.67% for PLK2
and 39.01% for PLK3, but the key contact residues have a high
similarity (Figure 5).
In particular, selectivity may be achievable by targeting the
Thr 477/Leu 478 (TL) pair at the end of the cryptic
hydrophobic pocket, which are TV in PLK2 and GI in PLK3.
In addition, the pair of residues Arg516/Phe535 are lysine and
tyrosine in PLK2 and PLK3. Measuring the selectivity of this
Figure 2. Optimized soluble analogue, compound 9, is active in FP (A) and isothermal titration calorimetry (ITC) (B) assays. (C) Activity of the
isolated enantiomers of compound 9 in the FP assay. For FP assays, values are the mean of three independent experiments ± SD. A representative
experiment is shown for ITC. The experiment was carried out in duplicate.
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Table 3. FP Results for a Set of Compound 1 Analogues Designed to Test the Predicted Binding Mode and Improve the
Binding Aﬃnitya
aAll IC50 values were measured by FP, and values represent the mean of three independent experiments ± standard deviation. ND = not
determinable. * Stereochemistries were assigned arbitrarily.
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series across the PLK family should be the focus of future
work.
■ CONCLUSIONS
This paper describes screening for PPI inhibitors and
subsequent hit identiﬁcation and optimization of a promising
new compound series for inhibition of the PBD of PLK1.
Protein−protein interactions have long been considered
challenging targets for drug discovery, and to address this,
we started with a PPI-focused library of approximately 86 000
commercially available compounds. Many of the primary hits
from FP screening were false positives, highlighting the need
for thorough validation and awareness of common liabilities.
Due to the nature of PPIs, poor compound solubility can be a
problem as many small-molecule inhibitors have signiﬁcant
hydrophobic character and derive their binding aﬃnity from
nonpolar interactions.33 In this case, poor solubility of the
primary hit precluded the initial advancement of the series, but
we were able to use molecular modeling to generate a
predicted binding pose, which guided the introduction of small
structural changes designed to improve solubility. It is worth
Figure 3. Dose-dependent increase in mitotic arrest with chromosome congression defects is caused upon treatment with Compound 9 and its
enantiomers. (A) Cells were treated with Compound 9 and its enantiomers, compounds (−)−9 and (+)−9 (at 200, 100, 50, 25, 12.5, 6.25, and 0
μM) and corresponding DMSO controls for 12 h. Mitotic cells scored as phospho-histone H3-stained cells per 2000 Hoechst 33342-stained nuclei
in a high-content screening platform as described earlier.27 Each bar is a mean of three replicates ± standard error of the mean (SEM). The data
presented is representative of two independent experiments. (B) HeLa cells were treated with compound (−)−9/DMSO for 12 h, as shown in A.
The cells were ﬁxed and stained for DNA and β-tubulin. Mitotic cells were identiﬁed by microscopy and scored under three categories: (a)
misaligned chromosomes and monopolar spindles, (b) misaligned chromosomes and bipolar spindles, and (c) aligned chromosomes and bipolar
spindles. The quantiﬁcation of the cellular phenotype is shown in the histogram. (C) Representative maximal-intensity projection images of cells in
each category (as in B) showing DNA in blue and spindle microtubules in red. The scale bar is 3 μm.
Figure 4. Treatment with compound (−)−9 causes mislocalization of PLK1 from kinetochores in mitotic cells. (A) Cells expressing GFP-PLK1
were treated with compound (−)−9 or DMSO for 9.5 h after double thymidine release. The cells were ﬁxed, stained for DNA (Hoechst) and
kinetochores (CREST antisera), and analyzed by immunoﬂuorescence microscopy. Prometaphase mitotic cells were identiﬁed based on DNA
morphology, and 1 μm confocal Z-stacks were taken for each cell. Quantiﬁcation of GFP-PLK1 intensity on CREST-stained kinetochores was
carried out using ImageJ. The data is represented as the Whisker maximum to minimum plot with a horizontal bar indicating mean GFP-PLK1
intensity on kinetochores. Statistical analysis was done using a nonparametric, Mann−Whitney two-tailed test with a 95% conﬁdence interval, **p
= 0.0037. 8 cells were analyzed for DMSO and 7 for compound (−)−9. (B) Representative maximal-intensity projection images of cells showing
CREST-stained kinetochores (red), GFP-PLK1 (green), and DNA (blue) used for quantiﬁcation of GFP-PLK1 intensity in Figure 4A. The scale
bar is 5 μm.
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noting that such improvements may be easier to achieve in
PPIs than traditional targets, due to the inherent solvent
exposure of the inhibitors.34 Sequence analysis suggests that
achieving selectivity for PLK1 over PLK2 and PLK3 may be
challenging but should be achievable by targeting speciﬁc
residues that diﬀer between these domains.
Thus, we have combined computational techniques,
synthetic chemistry, and a robust FP assay for the design,
synthesis, and characterization of analogues, with small
structural changes, to successfully remedy the solubility
problems and facilitate further development of the compound
series. This initial campaign has resulted in a cell-permeable,
small-molecule series with low molecular weight and evidence
of target engagement in both cell-free and cell-based assays.
Further work will be required to identify whether this is a
PLK1-speciﬁc or pan-PLK inhibitor. However, we propose that
this series may be a good candidate for further elaboration
towards chemical probe development and/or a cancer drug
discovery program.
■ METHODS
Library Design. The small-molecule library for high
throughput screening (HTS) was design and assembled in-
house from commercial vendors (Table 4).
The complete set of approximately 3 million compounds
was ﬁltered aggressively using the FILTER program (Open-
Eye). We employed the REOS substructure ﬁlters,35 Open-
Eye’s FILTER ﬁlters, and a set of physicochemical property
ﬁlters developed for PPI inhibitors (Table 5).
These criteria are wider than those typically used to generate
screening libraries,36 and these are based on recent studies.37,38
This ﬁltering step removed approximately 50% of the
compounds from consideration. The next stage was then
selection of a diverse subset of the remaining compounds. This
process was performed using directed sphere exclusion39 with
Canvas (Schrödinger, LLC). Each compound was assigned
radial ﬁngerprints40 with daylight atom types and a radius of 4.
The compound similarity was assessed using the Tanimoto
metric.41 Compounds were then selected iteratively, with the
requirement that no selected compound had a Tanimoto
similarity greater than 0.8 to any previously selected
compound. This process yielded a set of approximately
43 000 compounds. Each of these compounds was deﬁned as
the center of a cluster, and another molecule with a Tanimoto
similarity greater than 0.8 to the cluster center was randomly
selected for each cluster. This ensures that some basic SAR will
be present in the primary screening data. This led to the
selection of approximately 86 000 compounds. An additional
12 000 peptide-mimic compounds were also tested,42 bringing
the screening library to 98 000 compounds.
Protein Preparation. A region of the human PLK1 cDNA
sequence (residues 345−603) was ampliﬁed by polymerase
Figure 5. Sequence alignment of the PBDs of the PLK family. Sequences of human PLK1 residues 410−603, PLK2 residues 503−685, and PLK3
residues 463−646 were taken from UniProt. PLK4 and PLK5 were excluded from the analysis as they have markedly diﬀerent structures and
functions. The alignment was performed by Clustal Omega using default parameters. Residues in the phosphopeptide binding groove and cryptic
hydrophobic pocket are highlighted in bold. Residues in the phosphopeptide binding groove and cryptic hydrophobic pocket with complete
conservation across the PLK family are in red and those which diﬀer are in blue.
Table 4. Chemical Vendors Used to Source the HTS Library
supplier compounds available compounds selected
Asinex 364 407 9999
Chembridge 442 051 23 086
ChemDiv 789 603 20 000
Enamine 1 116 406 23 200
Life Chemicals 327 211 10 016
total 3 039 678 86 301
Table 5. Limits on the Physicochemical Properties Used to
Filter the HTS Library
property minimum maximum
molecular weight 250 650
number of heavy atoms 0 50
total charge −2 2
hydrogen bond acceptors 0 10
hydrogen bond donors 0 6
clog P −5.0 6.0
rotatable bonds 0 10
chiral centers 0 4
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chain reaction (PCR) and cloned into a pGEX-6P1 vector
(Invitrogen, Carlsbad, CA) to generate a recombinant protein
in C41 strain Escherichia coli.43 Bacteria were disrupted using
an Emulsiﬂex c5 homogenizer (Avestin), and lysates were
passed onto a glutathione S-transferase (GST)-Sepharose
column in the presence of 50 mM HEPES pH 7.5, 200 mM
NaCl, 1 mM EDTA, 1 mM EGTA, and 1 mM DTT. Bound
fractions were cleaved on the column at 4 °C overnight with
PreScission protease (GE healthcare). Puriﬁed fractions were
polished by gel chromatography using a Sephadex G25 (GE
healthcare) column, collected and concentrated. Fractions
were tested by Western blotting using the PLK1 antibody
(Invitrogen 33−1700) to validate protein puriﬁcation.
Fluorescence Polarization Assay. The HTS was
conducted using a ﬂuorescence polarization (FP) assay, as
described in Narvaez et al.23 All peptides and phosphopeptides
were synthesized using standard chemistry (Designer Bio-
science Ltd., Cambridge, U.K.). The ﬂuorescently labeled
probe was the phosphopeptide sequence MAGPMQSpTPLN-
GAKK with N-terminal TAMRA. FP measurements were
carried out in 384-well, low-volume, black, ﬂat-bottom
polystyrene N-bromosuccinimide (NBS) microplates (Corning
3820) using a PHERAstar Plus plate reader (BMGLabtech).
The ﬁnal assay volume of 45 μL contained a 10 nM labeled
probe peptide, 84 nM PBD, and varying concentrations of the
competitor. Assays were carried out in phosphate-buﬀered
saline (PBS) (pH 7.4) plus 0.03% tween. FP values were
obtained in millipolarization units at an excitation wavelength
of 540 nm and an emission wavelength of 590 nm.
Compounds were screened at an average concentration of
125 μM. All of the hits identiﬁed in the primary screen were
then reanalyzed at a range of concentrations to generate
dosimetry curves. DMSO controls were run alongside all
experimental compounds, and % inhibition was normalized to
these controls. The unlabeled LHSpT peptide was used as a
positive control. % inhibition values were calculated using
GraphPad Prism.
Isothermal Titration Calorimetry. ITC measurements
were performed in duplicate, as described in Narvaez et al.23 In
all titrations, protein PBD345−603 was used at 25 μM and
buﬀered in HEPES (50 mM, pH 7.4), NaCl (200 mM), and
DTT (1 mM). Protein was diluted into a buﬀer with DMSO at
5% (v/v). Compounds were prepared by diluting from DMSO
stock into the same buﬀer containing DMSO at 5% (v/v).
Great care was taken to match the concentration of DMSO in
the ligand and protein samples as closely as possible. In a
typical experiment, protein (25 μM) was loaded in the sample
cell, and a total of 20 injections of 8 μL were made at 2 min
intervals from a 200 μL syringe rotating at 1000 rpm and
loaded with the ligand solution (0.5 mM). In all titrations, an
initial injection of 2 μL ligand was made, and these data were
discarded during data analysis. The thermodynamic parameters
were obtained by ﬁtting the data to a single-site binding model
with a stoichiometry of 1. ITC experiments were performed at
20 °C with a MicroCal ITC200 instrument, and all data were
analyzed with the software implemented in Origin (version 7).
Turbidity Assay. 50 mM compound stock solutions in
DMSO were diluted to 250 μM in dH2O. 50 μL of the diluted
compounds was aliquoted into ﬂat-bottom 96-well plates and
incubated at room temperature for 20 min before absorbance
at 625 nM and it was read using a Tecan Inﬁnite 200 Pro plate
reader. Absorbance readings were normalized to DMSO
controls.
Binding Pose Prediction. Before analysis, all structures
were prepared using Schrödinger’s Preparation Wizard44 using
the default settings to check all protonation states as well as the
orientations of asparagine, glutamine, and histidine residues.
All water molecules were deleted prior to the analysis.
Molecular docking was performed using Schrödinger’s Glide
4.045 with the PDB structures 3BZI43 and 3P37.13 These
structures have the PLK1 PBD cryptic pocket in an open state,
as we believed that this hydrophobic pocket would be
important in binding small-molecule inhibitors. For the grid
generation and ligand docking procedures, the default Glide
settings were used. All structures were docked and scored using
the Glide extra-precision (XP)46 and rescored using an MM-
GBSA method.47
Cell Culture. HeLa FlpIn T-REx cells (a kind gift from
Professor Steve Taylor, University of Manchester) were
cultured at 37 °C under 5% CO2 in DMEM with GlutaMAX
(Life Technologies), supplemented with 10% fetal calf serum,
Zeocin (Invitrogen) at 0.05 mg/mL, and Blasticidin (Inviv-
oGen) at 4 μg/mL. All GFP-PLK1 HeLa FlpIn T-REx cell
lines were generated and maintained as described in Sharma et
al.15 Doxycycline (Sigma-Aldrich) at 0.1 mg/mL was used for
induction of the GFP-fusion protein.
Mitotic Index (MI) Assay. HeLa FlpIn T-REx cells were
arrested in early S-phase in growth media containing 2 mM
thymidine (Sigma) for 16 h. Cells were then released for 8 h in
thymidine-free media, and these were then arrested again with
thymidine for 16 h followed by the release in thymidine-free
media. Cells were treated for 12 h with DMSO or compounds,
and then these were ﬁxed in 3.7% formaldehyde (Agar
Scientiﬁc). Cells were permeabilized with 0.1% Triton X-100,
and then these were incubated with anti-phospho-histone H3
(Ser10) antibody (Abcam ab5176). The cells were washed
with PBS, and then these were incubated with Alexa Fluor 488-
labeled goat anti-rabbit IgG (Invitrogen A11034) in the
presence of 4 μg/mL Hoechst 33342 (Invitrogen H3570).
Cells were washed in PBS, and then these were imaged on an
Arrayscan VTi HCS instrument (Thermo Fisher) using the
Target Activation V4 BioApplication. Mitotic cells were scored
as phospho-histone H3-stained cells per 2000 Hoechst 33342-
stained nuclei, as described in Ibbeson et al.27
Immunoﬂuorescence (IF) and Image Analysis. Cells
were ﬁxed on a coverslip with 4% formaldehyde (Agar
Scientiﬁc) for 10 min. Cells were permeabilized with 0.1%
Triton-100 (Fisher), 0.1% Tween-20 (NBS Biologicals) in 1×
PBS (PBS-Triton-Tween) for 10 min and blocked with 1%
BSA (Fisher Scientiﬁc) in PBS-Triton-Tween for 30 min.
CREST antisera (Europa FZ90C-CS1058) was diluted 1:1000
in the blocking solution, and cells were incubated in humidiﬁed
chambers for 1 h at room temperature. The cells were then
washed with blocking solution, and the cells were incubated
with Alexa Fluor-conjugated secondary antibodies (Life
Technologies, 1:500) for 30 min. Cells were washed thrice
in the blocking solution and mounted in the 4,6-diamidino-2-
phenylindole (DAPI) containing medium (Vectashield). The
samples were stored in dark at 4 °C before microscopy. The
ﬁxed cell images were captured using a Leica SP5 confocal
microscope using a 63× or 100× 1.4 NA/oil objective with Z-
stacks of confocal slices taken at 1 μm intervals. Pixel
intensities were never saturated; laser exposure and detector
settings were identical between samples across an experiment.
The ImageJ software was used for image analysis. CREST
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staining was used as a mask to determine the average GFP-
PLK1 staining intensity in CREST-stained kinetochores.
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